PRMT5 and glioblastoma: Interestingly, GSCs that were more sensitive to PRMT5 inhibitors were more likely to be classified as proneural based on transcriptomics data, suggesting that patients with the proneural subtype of GBM may be more likely to derive benefit from treatment with PRMT5 inhibitors.